



The ERICCA trial

Effect of Remote Ischemic preConditioning on
clinical outcomes in patients undergoing Coronary
Artery bypass graft surgery:
A multi-center double-blind randomized controlled
clinical trial



British Heart Foundation

■ Efficacy and Mechanism
Evaluation programme




NHS
National Institute for
Health Research

Rationale

- Higher risk patients undergoing cardiac surgery
- Need for novel cardioprotective strategies
- Remote ischemic conditioning (RIC) can reduce peri-operative myocardial injury (PMI)
- *Can RIC improve long-term clinical outcomes?*


Remote ischemic conditioning

- Cycles of brief ischemia/ reperfusion can protect the heart and other organs
- Simple, non-invasive, low-cost intervention
- RIC potentially reduces PMI by 30 - 40%



1612 patients via 29 UK centres

CABG $\pm$ valve on-pump blood cardioplegia / Euroscore ≥ 5



Follow-up at one year

Recruitment completed March 2014

Primary combined endpoint

At one year post-randomization

- Cardiovascular death
- MI
- Stroke
- Coronary revascularization

Secondary endpoints

- 30 day MACCE
- Peri-operative myocardial injury
- Inotrope score
- Acute Kidney Injury
- Length of ITU/ Hospital stay


Baseline characteristics

Characteristic	Control N=811	RIC N=801
Male	586 (72%)	556 (69%)
Age (years)	76 (SD 7)	76 (SD 6)
Additive Euroscore	6.7 (SD 1.7)	6.6 (SD 1.6)
LVEF (%)	52 (SD 12)	52 (SD 13)
Diabetes	211 (26%)	203 (25%)
High cholesterol	554 (68%)	570 (71%)
Hypertension	599 (74%)	602 (75%)
Beta-blocker	471 (58%)	479 (60%)
Nitrates	223 (27%)	221 (28%)
Cholesterol-lowering	668 (82%)	641 (80%)
ACE-I	391 (48%)	428 (53%)


Surgery characteristics

Characteristic	Control N=811	RIC N=801
CABG + valve surgery	406 (51%)	371 (47%)
Cardiopulmonary bypass time (min)	112 (SD 50)	112 (SD 51)
Cross-clamp time (min)	76 (SD 40)	74 (SD39)
Volatile anesthesia (Isoflurane/Sevoflurane)	321 (40%)	324 (41%)
Propofol	706 (87%)	721 (90%)
IV Nitrates	230 (28%)	233 (29%)
Fentanyl	660 (81%)	658 (82%)
Morphine	236 (29%)	241 (30%)

Primary combined endpoint



Primary combined endpoint



Primary combined endpoint

Endpoint	Control N=811		RIC N=801		P-value
	N	%	N	%	
MACCE	227	28.0	213	26.6	0.55
CV Death	32	3.9	46	5.7	0.10
MI	192	23.7	175	21.8	0.43
Stroke	18	2.2	16	2.0	0.77
Revasc	4	0.5	2	0.2	0.43

Secondary endpoints

Endpoint	Control		RIC		P-value
	Med	IQR	Med	IQR	
Peri-operative myocardial injury (72 hr AUC hsTrop-T)	35,730 N=369	22,812-57,207	30,500 N=366	20,481-54,186	0.039
Inotrope score	5.6 N=793	0.0 -15.5	6.0 N=772	0.0-14.9	0.98
ITU stay	3 N=793	1-5	3 N=779	1-4	0.22
Hospital stay	10 N=793	7-17	10 N=779	7-16	0.19

Secondary endpoints

Endpoint	Control N=772		RIC N=749		P-value
	N	%	N	%	
AKI	293	38	287	38	0.98
Stage 1	226	29.3	230	30.7	
Stage 2	44	15.7	38	5.1	
Stage 3	23	3.0	19	2.5	

Discussion

- Multiple causes of PMI
- Co-morbidities and concomitant medication can affect RIC
- Some neutral small clinical studies
- PMI as a surrogate marker of cardioprotection

Conclusions

- RIC did not improve long-term clinical outcomes in high-risk patients undergoing on-pump cardiac bypass surgery with blood cardioplegia
- In other settings of ischemia/reperfusion injury such as STEMI (CONDI2/ERIC-PPCI) and organ transplantation (REPAIR) the effect of RIC on major clinical outcomes remains to be investigated

Acknowledgements

The Hatter Cardiovascular Institute, UCL

Luciano Candilio
Maria Xenou
Derek Yellon

LSHTM CTU

Tim Clayton
Rosemary Knight
Richard Evans
Steven Robertson
Jo Astarci
Jennifer Nicholas
Cono Ariti



British Heart Foundation

Trial Steering Committee

Chair: David Taggart

Data Monitoring Committee

Chair: Rajesh Kharbanda

End-point Validation Committee

Chair: Simon Kendall

Recruiting Centres

All patients, research nurses and
staff

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



■ Efficacy and Mechanism
Evaluation programme



NHS
National Institute for
Health Research